Biofrontera (AI10) Stock Price & Analysis

1 Followers

AI10 Stock Chart & Stats

€0.80€0.00(0.00%)

At close: Nov 12 5:30 PM GMT+1

Day’s Range: EUR 0.79 - EUR 0.80
52-Week Range: EUR 0.79 - EUR 0.80
Previous Close: EUR 0.80
Volume: N/A
Average Volume (3M): 0
Market Cap: EUR 12.59M
Enterprise Value: EUR 15.06M
Total Cash (Recent Filing): EUR 4.67M
Total Debt (Recent Filing): EUR 7.50M
Price to Earnings (P/E): ―
Beta: N/A
Next Earnings: Mar 19, 2027 (Est.)
EPS Estimate: 0.28
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Strong revenue and Ameluz volume growth indicate improving commercial execution and broader utilization of the company’s dermatology platform. Continued growth in orders, tubes per order, and purchasing locations could strengthen operating leverage and support expansion over the next several quarters.

Expanded Ameluz Indication

FDA approval for superficial basal cell carcinoma expands Ameluz’s addressable market while leveraging the company’s existing gel, lamps, sales infrastructure, and dermatology relationships. This creates a durable commercial opportunity beyond actinic keratosis and may support new practice adoption.

Improved Gross Margin

The substantial margin rebound suggests the strategic transaction and Ameluz cost structure have improved product economics. Higher gross profit per dollar of revenue can provide greater capacity to fund selling efforts, absorb regulatory costs, and move the business toward break-even.

Bears Say

Going-Concern Risk

A formal going-concern warning indicates that current resources and expected operating cash generation may not be sufficient to sustain the business without additional financing or other mitigation. This can constrain strategic flexibility and make execution of the growth plan dependent on external capital.

Persistent Cash Burn

Persistent negative cash generation means the company is still funding operations externally rather than through its commercial business. Even with improved revenue and margins, continued burn can consume liquidity, limit investment in launches, and increase dependence on financing or milestone proceeds.

Weak Equity Cushion And Compliance

A stockholders’ deficit and failure to meet NASDAQ equity requirements reflect a materially weakened balance sheet. This raises compliance pressure and may force capital-raising or restructuring actions, while reducing the financial cushion available to absorb further losses or execution setbacks.

Biofrontera News

Biofrontera submits sNDA to FDA to expand Ameluz indication

Biofrontera (BFRI) announced that it has submitted a supplemental new drug application, or sNDA, to the FDA to expand the indication for Ameluz topical gel, 10%, in combination with PDT

1M agoBFRI AI10

Biofrontera Gains FDA Approval for Ameluz Skin Cancer Use

Biofrontera ( ($BFRI) ) has provided an announcement. On September 14, 2026, Biofrontera announced that the U.S. Food and Drug Administration approved a supplemental New Drug Application for Ameluz 10%

2M ago8K BFRI

Biofrontera announces FDA approval of Ameluz supplemental new drug application

Biofrontera (BFRI) announced that the FDA has approved the company’s supplemental new drug application, or sNDA, for Ameluz topical gel, 10%, in combination with photodynamic therapy using the BF-RhodoLED lamp

2M agoBFRI AI10

FDA approves label update for Biofrontera’s Ameluz Gel

The updated label for Ameluz Gel was posted to the FDA’s website. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the

2M agoBFRI AI10

Biofrontera Earnings Call Highlights Growth Amid Legal Risks

Biofrontera, Inc. (($BFRI)) has held its Q2 earnings call. Read on for the main highlights of the call. Biofrontera’s latest earnings call struck a notably upbeat tone, with management emphasizing

2M agoBFRI AI10

Is BFRI a Buy, Before Earnings?

Biofrontera, Inc. (BFRI) is scheduled to report 2nd quarter earnings on 08/13/2026, before the market opens. Regarding Q2 estimates, Wall Street analysts expect Biofrontera, Inc. to post earnings of -$0.11

3M agoBFRI AI10

BFRI Upcoming Earnings Report: What to Expect?

Biofrontera, Inc. (BFRI) is scheduled to report 2nd quarter earnings on 08/07/2026. Regarding Q2 estimates, Wall Street analysts expect Biofrontera, Inc. to post earnings of -$0.11 per share. Revenue expectations

3M agoBFRI AI10

Biofrontera’s Acne PDT Trial Completion: What Investors Should Watch Next

Biofrontera, Inc. ($BFRI) announced an update on their ongoing clinical study. Biofrontera Inc. is advancing a Phase II study called “A Randomized, Double Blind, Vehicle-controlled, Multicenter Phase II Study to

4M agoBFRI

Biofrontera’s Phase III Actinic Keratosis Study Nears Data Payoff for Investors

Biofrontera, Inc. ($BFRI) announced an update on their ongoing clinical study. Biofrontera Inc. is running a Phase III study called “A Randomized, Double-blind, Vehicle-controlled, Multicenter Phase III Study…” to test

4M agoBFRI

Biofrontera Shareholders Approve Director Elections and Equity Plan

Biofrontera ( ($BFRI) ) just unveiled an update. At its Annual Meeting of Stockholders held on June 11, 2026, Biofrontera Inc. shareholders elected Beth J. Hoffman, Ph.D., and Kevin D.

4M ago8K BFRI

Biofrontera Earnings Call Highlights Growth And Risks

Biofrontera, Inc. (($BFRI)) has held its Q1 earnings call. Read on for the main highlights of the call. Biofrontera, Inc.’s latest earnings call struck a cautiously optimistic tone, as strong

5M agoBFRI AI10

StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

5M agoAMT BAP

Biofrontera downgraded to Speculative Buy from Buy at Benchmark

Benchmark analyst Bruce Jackson downgraded Biofrontera (BFRI) to Speculative Buy from Buy with a $3 price target after the company reported in line Q1 results and reiterated its plans to

5M agoBFRI AI10

Is BFRI a Buy, Before Earnings?

Biofrontera, Inc. (BFRI) is scheduled to report 1st quarter earnings on 05/08/2026. Regarding Q1 estimates, Wall Street analysts expect Biofrontera, Inc. to post earnings of -$0.12 per share. Revenue expectations

6M agoBFRI AI10

AI10 FAQ

What was Biofrontera’s price range in the past 12 months?

Biofrontera lowest stock price was €0.79 and its highest was €0.80 in the past 12 months.

What is Biofrontera’s market cap?

Biofrontera’s market cap is €12.59M.

When is Biofrontera’s upcoming earnings report date?

Biofrontera’s next earnings report is estimated for Mar 19, 2027 (not yet confirmed), which is in 126 days.

How were Biofrontera’s earnings last quarter?

Biofrontera released its earnings results on Nov 13, 2026. The company reported -€0.38 earnings per share for the quarter, missing the consensus estimate of -€0.099 by -€0.28.

Is Biofrontera overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Biofrontera pay dividends?

Biofrontera does not currently pay dividends.

What is Biofrontera’s EPS estimate?

Biofrontera’s EPS estimate is 0.28.

How many shares outstanding does Biofrontera have?

Biofrontera has 14,852,359 shares outstanding.

What happened to Biofrontera’s price movement after its last earnings report?

Biofrontera reported an EPS of -€0.38 in its last earnings report, missing expectations of -€0.099. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Biofrontera?

Currently, no hedge funds are holding shares in DE:AI10

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Biofrontera

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Biofrontera (AI10) Earnings & Revenues

Historic Earnings Reports

AI10 Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call SentimentNeutral

The call presented substantial regulatory, commercial, and operational progress, including a second approved indication, clearance of the RhodoLED XLC, strong revenue and volume growth, improved margins, and preparation for additional label expansion. However, these positives were offset by continued net losses, ITC-related costs, declining cash, a NASDAQ stockholders' equity deficiency, and management's disclosure that substantial doubt remains about the company's ability to continue as a going concern. Overall, the positive business developments and financial improvements were balanced by significant liquidity and compliance risks.

View all DE:AI10 earnings summaries

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	3	5	9
Technical Analysis	1	1	3
Moving Averages	2	4	6

Technical Analysis >

Similar Stocks

Stocks similar to DE:AI10
Company	Price & Change	Follow
PRPHProphase Labs
TXMDTherapeuticsMD
RDHLRedHill Biopharma
COSMCosmos Holdings
GELSGelteq Limited

Compare DE:AI10 Stocks >

Ownership Overview

3.76% Insiders
0.98% Mutual Funds
10.08% Other Institutional Investors
84.61% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

AI10 Stock Chart & Stats

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Expanded Ameluz Indication

Improved Gross Margin

Bears Say

Going-Concern Risk

Persistent Cash Burn

Weak Equity Cushion And Compliance

Biofrontera News

Biofrontera submits sNDA to FDA to expand Ameluz indication

Biofrontera Gains FDA Approval for Ameluz Skin Cancer Use

Biofrontera announces FDA approval of Ameluz supplemental new drug application

FDA approves label update for Biofrontera’s Ameluz Gel

Biofrontera Earnings Call Highlights Growth Amid Legal Risks

Is BFRI a Buy, Before Earnings?

BFRI Upcoming Earnings Report: What to Expect?

Biofrontera’s Acne PDT Trial Completion: What Investors Should Watch Next

Biofrontera’s Phase III Actinic Keratosis Study Nears Data Payoff for Investors

Biofrontera Shareholders Approve Director Elections and Equity Plan

Biofrontera Earnings Call Highlights Growth And Risks

StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls

Biofrontera downgraded to Speculative Buy from Buy at Benchmark

Is BFRI a Buy, Before Earnings?

AI10 FAQ

Company Description

Biofrontera

Biofrontera (AI10) Earnings & Revenues

AI10 Earnings Call

Earnings Call Sentiment|Neutral

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentNeutral